LA
BIO icon

Lee Ainslie’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lee Ainslie’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,082
Closed -$1.48M – 416
2023
Q1 		$1.48M Buy
3,082
+2,447
+385% +$1.15M 0.04% 103
2022
Q4 		$267K Buy
+635
New +$256K 0.01% 315
2021
Q3 		– Sell
-273
Closed -$176K – 651
2021
Q2 		$176K Buy
273
+50
+22% +$30.4K ﹤0.01% 500
2021
Q1 		$127K Sell
223
-193
-46% -$114K ﹤0.01% 552
2020
Q4 		$243K Buy
+416
New +$237K ﹤0.01% 492
2020
Q3 		– Sell
-915
Closed -$413K – 580
2020
Q2 		$413K Buy
+915
New +$404K 0.01% 462

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Lee Ainslie's BIO Position: Q2 2023 in Review

Lee Ainslie sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 3,082 shares — an estimated $1.48M sold.

Lee Ainslie first reported a position in BIO in Q2 2020 and held it in 6 quarters. The position peaked at $1.48M in Q1 2023. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Lee Ainslie reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Lee Ainslie sold 3,082 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $1.48M.
  • Lee Ainslie first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 6 quarters.
  • Lee Ainslie's Bio-Rad Laboratories Class A position peaked at $1.48M in Q1 2023.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Maverick Capital's 13F filing for Q2 2023, filed 14 Aug 2023.